Biotech is a topic tracked in our intelligence system with 5 linked articles.
FDA approves Ultragenyx gene therapy and Regeneron secures ultra-rare disease approval, underscoring regulatory momentum for gene therapies and mRNA platforms, per The Readout.
A teaser-style health-news item focusing on contrasting legal decisions about gender-affirming care and other health topics.
Capricorâs Duchenne cell therapy is at risk of FDA rejection, with the company attempting to stave off the decision.
Regulatory scrutiny around Huidagene's disclosures after a patient death; mentions Merck/Moderna mRNA cancer vaccine and a potential FDA leadership nomineeâsignals regulatory and approval risk in biotech.
Experts scrutinize Huidagene's gene-editing approach for Duchenne after a fatal case, highlighting concerns about a strategy largely abandoned by U.S. firms.
Moderna and Merck report a late-stage trial success for a personalized mRNA melanoma vaccine.
Subscribe for real-time topic updates and unlimited access to our intelligence platform.